# Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

> **NCT01576666** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Dose Escalation
- Safety
- Preliminary Efficacy
- Advanced Solid Tumors
- Metastatic Breast Cancer
- Advanced Pancreatic Adenocarcinoma
- Metastatic Colorectal Cancer
- Recurrent Glioblastoma Multiforme
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Triple Negative Metastatic Breast Cancer
- Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer

## Interventions

- **DRUG:** LDE225
- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT01576666
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01576666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01576666, "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01576666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*